Abstract
Cannabinoid receptor agonists, such as Δ9-THC, the primary active constituent of Cannabis sativa, have anti-pyrogenic effects in a variety of assays. Recently, attention has turned to the endogenous cannabinoid system and how endocannabinoids, including 2-arachidonoylglycerol (2-AG) and anandamide, regulate multiple homeostatic processes, including thermoregulation. Inhibiting endocannabinoid catabolic enzymes, monoacylglycerol lipase (MAGL) or fatty acid amide hydrolase (FAAH), elevates levels of 2-AG or anandamide in vivo, respectively. The purpose of this experiment was to test the hypothesis that endocannabinoid catabolic enzymes function to maintain thermal homeostasis in response to hypothermic challenge. In separate experiments, male C57BL/6J mice were administered a MAGL or FAAH inhibitor, and then challenged with the bacterial endotoxin lipopolysaccharide (LPS; 2 mg/kg ip) or a cold (4 °C) ambient environment. Systemic LPS administration caused a significant decrease in core body temperature after 6 h, and this hypothermia persisted for at least 12 h. Similarly, cold environment induced mild hypothermia that resolved within 30 min. JZL184 exacerbated hypothermia induced by either LPS or cold challenge, both of which effects were blocked by rimonabant, but not SR144528, indicating a CB1 cannabinoid receptor mechanism of action. In contrast, the FAAH inhibitor, PF-3845, had no effect on either LPS-induced or cold-induced hypothermia. These data indicate that unlike direct acting cannabinoid receptor agonists, which elicit profound hypothermic responses on their own, neither MAGL nor FAAH inhibitors affect normal body temperature. However, these endocannabinoid catabolic enzymes play distinct roles in thermoregulation following hypothermic challenges.
This is a preview of subscription content, access via your institution.



Abbreviations
- 2-AG:
-
2-arachidonoylglycerol
- AA:
-
Arachidonic acid
- Anandamide:
-
N-arachidonoylethanolamine
- CB1 :
-
Cannabinoid receptor type 1
- CB2 :
-
Cannabinoid receptor type 2
- FAAH:
-
Fatty acid amide hydrolase
- JZL184:
-
4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate
- MAGL:
-
Monoacylglycerol lipase
- Tb :
-
Body temperature
- THC:
-
Δ9-tetrahydrocannabinol
- TNFα:
-
Tumor necrosis factor α
References
Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, Stevens RC, Cravatt BF (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16:411–420
Al-Saffar H, Lewis K, Liu E, Schober A, Corrigan JJ, Shibata K, Steiner AA (2013) Lipopolysaccharide-induced hypothermia and hypotension are associated with inflammatory signaling that is triggered outside the brain. Brain Behav Immun 28:188–195
Benamar K, Yondorf M, Meissler JJ, Geller EB, Tallarida RJ, Eisenstein TK, Adler MW (2007) A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide. J Pharmacol Exp Ther 320:1127–1133
Beutler B, Rietschel ET (2003) Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 3:169–176
Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernandez-Ruiz JJ, Di Marzo V (1999) Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 256:377–380
Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347–1356
Burston JJ, Sim-Selley LJ, Harloe JP, Mahadevan A, Razdan RK, Selley DE, Wiley JL (2008) N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. J Pharmacol Exp Ther 327:546–553
Compton DR, Aceto MD, Lowe J, Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586–594
Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98:9371–9376
Darwazeh R, Yan Y (2013) Mild hypothermia as a treatment for central nervous system injuries: positive or negative effects. Neural Regen Res 8:2677–2686
Fant RV, Heishman SJ, Bunker EB, Pickworth WB (1998) Acute and residual effects of marijuana in humans. Pharmacol Biochem Behav 60:777–784
Fitton AG, Pertwee RG (1982) Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of D9-tetrahydrocannabinol. Br J Pharmacol 75:409–414
Fraga D, Zanoni CI, Rae GA, Parada CA, Souza GE (2009) Endogenous cannabinoids induce fever through the activation of CB1 receptors. Br J Pharmacol 157:1494–1501
Freeman AS, Martin BR (1983) Interactions between phencyclidine and delta 9-tetrahydrocannabinol in mice following smoke exposure. Life Sci 32:1081–1089
Hollister LE (1971) Actions of various marihuana derivatives in man. Pharmacol Rev 23:349–357
Holtzman D, Lovell RA, Jaffe JH, Freedman DX (1969) 1-D9-Tetrahydrocannabinol: neurochemical and behavioral effects in the mouse. Science 163:1464–1467
Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE (1975) Effects of Ð9-tetrahydrocannabinol and cannabinol in man. Pharmacology 13:502–512
Kinsey SG, Long JZ, O’Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330:902–910
Kinsey SG, Mahadevan A, Zhao B, Sun H, Naidu PS, Razdan RK, Selley DE, Imad Damaj M, Lichtman AH (2011) The CB(2) cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology 60:244–251
Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, Lichtman AH (2013) Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345:492–501
Lichtman AH, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger D, Cravatt BF (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441–448
Long JZ, Nomura DK, Cravatt BF (2009a) Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16:744–753
Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF (2009b) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37–44
Malone DT, Taylor DA (1998) Modulation of delta9-tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. Br J Pharmacol 124:1419–1424
Martin BR, Balster RL, Razdan RK, Harris LS, Dewey WL (1981) Behavioral comparisons of the stereoisomers of tetrahydrocannabinols. Life Sci 29:565–574
Nava F, Carta G, Gessa GL (2000) Permissive role of dopamine D(2) receptors in the hypothermia induced by delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 66:183–187
Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334:809–813
Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085–2088
Rawls SM, Cabassa J, Geller EB, Adler MW (2002) CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212–2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrr olo[3,2,1ij]quinolin-6-one]-induced hypothermia. J Pharmacol Exp Ther 301:963–968
Rawls SM, Tallarida RJ, Kon DA, Geller EB, Adler MW (2004) GABAA receptors modulate cannabinoid-evoked hypothermia. Pharmacol Biochem Behav 78:83–91
Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244
Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere JC, Le Fur GL (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644–650
Romanovsky AA (2007) Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system. Am J Physiol Regul Integr Comp Physiol 292:R37–R46
Steiner AA, Molchanova AY, Dogan MD, Patel S, Petervari E, Balasko M, Wanner SP, Eales J, Oliveira DL, Gavva NR, Almeida MC, Szekely M, Romanovsky AA (2011) The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. J Physiol 589:2415–2431
Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605–612
Wiley JL, Martin BR (2003) Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol 471:185–193
Wong KC (1983) Physiology and pharmacology of hypothermia. West J Med 138:227–232
Acknowledgments
We thank Scott O’Neal and Molly Crowe for technical assistance. Financial support was provided by the National Institutes of Health, grants [T32DA007027, P01DA009789, P01DA017259, P50DA005274, R01DA030404, and R01DA015197].
Author Contributions
Participated in research design: Nass, Long, Schlosburg, Cravatt, Lichtman, Kinsey
Conducted experiments: Nass, Kinsey
Performed data analysis: Nass, Kinsey
Wrote or contributed to the writing of the manuscript: Nass, Lichtman, Kinsey
Compliance with Ethical Standards
ᅟ
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nass, S.R., Long, J.Z., Schlosburg, J.E. et al. Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge. J Neuroimmune Pharmacol 10, 364–370 (2015). https://doi.org/10.1007/s11481-015-9593-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-015-9593-1